Diagnosia
The leading European source for medical drug information intended for both patients and physicians in 14 languages..
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Early VC | ||
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (82 %) | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Diagnosia Internetservices GmbH operates as a specialized developer of a drug information platform for medical professionals. The Vienna-based company was established in 2011 by Lukas Zinnagl, Marco Vitula, and Fritz Höllerer. Zinnagl, a medical doctor by training, transitioned to technology and entrepreneurship, driven by a desire to solve systemic healthcare problems through software. This medical background provided the foundational insight for the company's core product.
The firm's primary offerings are a mobile and web-based application, Diagnosia Mobile, and an integrated hospital software, Diagnosia Enterprise. These tools function as a drug decision support engine, providing healthcare professionals with rapid access to information on medications, including dosages, interactions, side effects, and administrative guidelines. The platform's main value proposition is enabling clinicians to make more informed medication decisions at the point of care, thereby enhancing treatment quality and patient safety. Key features include a fast search function, an evidence-based drug database, an interaction checker, and a barcode scanner for quick medication identification.
Diagnosia's business model is twofold. For individual professionals, the app serves as an indispensable daily tool. For hospitals and healthcare facilities across Austria, Germany, and Switzerland, the company provides its 'Enterprise' software as an integrated solution, making it a B2B SaaS provider. A significant revenue stream is also generated by offering pharmaceutical companies a targeted marketing channel within the platform to reach a highly specific audience of medical professionals. In March 2021, the Austrian Apotheker-Verlag acquired a majority stake in the company, a strategic move aimed at expanding the client base to include pharmacists and bolstering the enterprise product. Prior to its acquisition, Diagnosia had raised approximately $1.7 million over several funding rounds from investors including Speedinvest and business angel Hansi Hansmann.
Keywords: drug information, clinical decision support, HealthTech, medical software, B2B SaaS, pharmaceutical marketing, medication management, mobile health, hospital software, physician tools